Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations

Blood

Volumn 124, Issue 17, 2014, Pages 2657-2665

  Gragert, Loren ^a   Fingerson, Stephanie ^a   Albrecht, Mark ^a   Maiers, Martin ^a   Kalaycio, Matt ^b   Hill, Brian T ^b  

^a NATIONAL MARROW DONOR PROGRAM   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA DRB4 ANTIGEN; HLA ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TRANSPLANTATION; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HISPANIC; HLA SYSTEM; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; UNITED STATES; VOLUNTEER; ADOLESCENT; ALLELE; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HISTOCOMPATIBILITY TEST; MIDDLE AGED; PROCEDURES; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; ALLELES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HISPANIC AMERICANS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; ODDS RATIO; UNITED STATES; YOUNG ADULT;

EID: 84908254159     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-558767     Document Type: Article

References (58)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
3. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103(4):1202-1210.
4. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014.
5. Boggs DR, Chen SC, Zhang Z-N, Zhang A. Chronic lymphocytic leukemia in China. Am J Hematol. 1987;25(3):349-354.
6. Mak V, Ip D, Mang O, et al. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008. Leuk Lymphoma. 2013;55(4):824-827.
7. Pan JWY, Cook LS, Schwartz SM, Weis NS. Incidence of leukemia in Asian migrants to the United States and their descendants. Cancer Causes Control. 2002;13(9):791-795.
8. Sava GP, Speedy HE, Houlston RS. Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55(1):160-167.
9. Brown JR. Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. Ther Adv Hematol. 2013;4(4):298-308.
10. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008;180(6):3969-3979.
11. Coombs CC, Rassenti LZ, Falchi L, et al. Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood. 2012;120(8):1687-1690.
12. Houlston RS, Sellick G, Yuille M, Matutes E, Catovsky D. Causation of chronic lymphocytic leukemia - insights from familial disease. Leuk Res. 2003;27(10):871-876.
13. Sellick GS, Catovsky D, Houlston RS. Familial chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):195-201.
14. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137-148.
15. Verheyden S, Ferrone S, Mulder A, et al. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother. 2009;58(6):855-865.
16. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1(1):41-49.
17. Drénou B, Le Friec G, Bernard M, et al. Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. Br J Haematol. 2002;119(2):417-424.
18. Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14(July):301-323.
19. Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol. 2013;74(10):1313-1320.
20. Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013;45(8):868-876.
21. Slager SL, Camp NJ, Conde L, et al. Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. Br J Haematol. 2012;159(5):572-576.
22. Slager SL, Rabe KG, Achenbach SJ, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011;117(6):1911-1916.
23. Di Bernardo MC, Broderick P, Harris S, et al. Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation. Leukemia. 2013;27(1):255-258.
24. Dorak MT, Machulla HK, Hentschel M, Mills KI, Langner J, Burnett AK. Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia. Int J Cancer. 1996;65(2):134-139.
25. Erlich H. HLA DNA typing: past, present, and future. Tissue Antigens. 2012;80(1):1-11.
26. Gourraud P-A, Lamiraux P, El-Kadhi N, Raffoux C, Cambon-Thomsen A. Inferred HLA haplotype information for donors from hematopoietic stem cells donor registries. Hum Immunol. 2005;66(5):563-570.
27. Paunić V, Gragert L, Madbouly A, Freeman J, Maiers M. Measuring ambiguity in HLA typing methods. PLoS ONE. 2012;7(8):e43585.
28. Madbouly A, Gragert L, Freeman J, et al. Validation of statistical imputation of allele-level multilocus phased genotypes from ambiguous HLA assignments. Tissue Antigens. 2014;84(3):285-292.
29. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley and Sons; 1987.
30. Gumperz JE, Barber LD, Valiante NM, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol. 1997;158(11):5237-5241.
31. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305(5685):872-874.
32. Schafer JL. Analysis of Incomplete Multivariate Data. New York: Chapman & Hall; 1997.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57(1):289-300.
34. Fabrigar LR, Wegener DT. Exploratory Factor Analysis (Understanding Statistics). Oxford, UK: Oxford University Press; 2011.
35. Cattell RB. The Scree test for the number of factors. Multivariate Behav Res. 1966;1(2):245-276.
36. National Cancer Institute. SEER: Surveillance, Epidemiology, and End Results program. http://www.seer.cancer.gov/data. Accessed December 7, 2012.
37. Shvidel L, Shtarlid M, Klepfish A, Sigler E, Berrebi A. Epidemiology and ethnic aspects of B cell chronic lymphocytic leukemia in Israel. Leukemia. 1998;12(10):1612-1617.
38. Klitz W, Gragert L, Maiers M, et al. Genetic differentiation of Jewish populations. Tissue Antigens. 2010;76(6):442-458.
39. Leslie S, Donnelly P, McVean G. A statistical method for predicting classical HLA alleles from SNP data. Am J Hum Genet. 2008;82(1):48-56.
40. Montes-Ares O, Moya-Quiles MR, Montes-Casado M, et al. Human leucocyte antigen-C in B chronic lymphocytic leukaemia. Br J Haematol. 2006;135(4):517-519.
41. Shah N, Decker WK, Lapushin R, et al. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia. 2011;25(6):1036-1039.
42. Mueller LP, Machulla HKG. Increased frequency of homozygosity for HLA class II loci in female patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43(5):1013-1019.
43. Wang SS, Abdou AM, Morton LM, et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood. 2010;115(23):4820-4823.
44. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today. 1990;11(4):137-142.
45. den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for HLA-B27? AIDS Rev. 2004;6(2):89-96.
46. Guillaume N, Marolleau J-P. Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies. Leuk Res. 2013;37(4):473-477.
47. Demanet C, Mulder A, Deneys V, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 2004;103(8):3122-3130.
48. Andersson E, Villabona L, Bergfeldt K, et al. Correlation of HLA-A02∗ genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother. 2012;61(8):1243-1253.
49. Ruchlemer R, Polliack A. Geography, ethnicity and "roots" in chronic lymphocytic leukemia. Leuk Lymphoma. 2012; (October):1-9.
50. Rajasagi M, Shukla SA, Fritsch EF, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453-462.
51. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139(5):809-819.
52. Shenoy PJ, Malik N, Sinha R, et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011;11(6):498-506.
53. Falchi L, Keating MJ, Wang X, et al. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer. 2013;119(17):3177-3185.
54. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
55. Chavez JC, Kharfan-Dabaja MA, Kim J, et al. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia [published online ahead of print April 28, 2014]. Leuk Res. doi:10.1016/j.leukres.2014.04.006.
56. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
57. Hawkins OE, Vangundy RS, Eckerd AM, et al. Identification of breast cancer peptide epitopes presented by HLA-A∗0201. J Proteome Res. 2008;7(4):1445-1457.
58. Weidanz JA, Hawkins O, Verma B, Hildebrand WH. TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells. Int Rev Immunol. 2011;30(5-6):328-340.